Target intelligence / Profile preview

Gastric volume reduction

Molecular classification
Other
01

Overview

Gastric volume reduction refers broadly to medical interventions that decrease the functional size/capacity of the stomach. This can be accomplished surgically—for example, via sleeve gastrectomy where approximately three-fourths of the stomach is removed—or through less invasive endoscopic methods such as transoral suturing/plication. The primary goal is physical restriction leading to earlier satiation after smaller meals and sustained caloric deficit resulting in weight loss. These procedures also induce changes in gut hormone profiles—including reductions in ghrelin and increases in GLP‑1/PYY—which further suppress appetite and improve glucose metabolism. While highly effective for obesity management, these interventions carry risks including perioperative complications and long-term nutritional deficiencies if dietary supplementation is inadequate. Importantly, “gastric volume reduction” itself does not denote any single molecular entity but rather describes an anatomical change produced by diverse procedural approaches.[1][2][4][5][10]

Other names
Stomach volume reductionGastric capacity reductionBariatric restriction
02

Mechanism of action

Procedures that achieve gastric volume reduction work via: - Physical restriction—reducing stomach reservoir capacity so less food can be ingested before feeling full[5][10]. - Hormonal modulation—altering levels of hormones such as ghrelin (decreases hunger), GLP‑1 and PYY (increase satiety)[1]. - Neuromodulation—affecting vagal signaling related to hunger/satiety. Some pharmacologic agents slow gastric emptying or modulate gut hormones but do not physically reduce stomach size.

03

Biological functions

Regulation of food intakeInduction of satiety/fullnessModulation of gut hormone secretionAlteration of gastrointestinal motility
04

Disease associations

ObesityType 2 diabetes mellitus (as comorbidity improved by weight loss)
05

Safety considerations

Surgical risks/infection/bleeding/leakage at staple lines/plicationsNutritional deficiencies due to reduced intake/absorption (notably B vitamins)Durability concerns with some endoscopic techniques due to partial release/loss of plications over timeBand slippage/erosion/migration
06

Interacting drugs

None directly.
07

Biomarkers

BMI and waist circumference are used clinically to select candidates for bariatric procedures.Changes in HbA1c may be monitored post-procedure for metabolic improvement

Beyond the preview

Go deeper on Gastric volume reduction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric volume reduction.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call